Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment
European Journal of Cancer · 2026-01 · 232 · 116160
DOI: 10.1016/j.ejca.2025.116160 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-01. Verfasst von Mélanie Debiais und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France. Electronic address: melanie.debiais@gustaveroussy.fr. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
BACKGROUND: Metastatic pancreatic adenocarcinoma (mPDAC) has a poor prognosis. FOLFIRINOX (FFX) and gemcitabine nab-paclitaxel (GN) are the preferred first line (L1) regimens. We evaluated real-world outcomes of L1 therapies. METHODS: Retrospective analysis of all patients who received L1 chemotherapy for mPDAC between 2010 and 2024 at a single academic comprehensive cancer center. RESULTS: A total of 1012 patients were included: 48 % women, median age 63 years, 91 % ECOG 0-1. Synchronous metastases occurred in 66 % of patients. Liver (67 %), lung (20 %) and peritoneum (20 %) were the most frequent sites of metastasis. L1 regimens were FFX (n = 621, 61 %), gemcitabine (Gem) (141, 14 %), GN (78, 8 %), and others (n = 172, 17 %). Compared with GN, FFX recipients were younger (61 vs 65 years, p < 0.0001) with better ECOG (≥ 2 in 4 % vs 13 %, p < 0.0001). Median OS was 14.5 months (95 %CI [13.3-15.8]) with FFX, 12.4 [9.4-21.9] with GN, 7.9 [6.5-10.7] with Gem and 9.2 [7.2-13.1] with others (p < 0.0001). Respective median PFS were 7.0 months [95 %CI: 6.5-7.9], 5.4 [4.0-8.3], 4.9 [3.6-6.0] and 5.6 [3.6-7.0] (p < 0.05). CONCLUSIONS: In this large real-world cohort, FFX was associated with superior response rate, PFS, and OS compared with other L1 regimens, supporting its use as standard first-line therapy for mPDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France. Electronic address: melanie.debiais@gustaveroussy.fr.
- Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France.
- Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
- Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Université Paris Saclay, Villejuif 94805, France.
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Debiais, M., Tarabay, A., Blanchet-Deverly, S., Camilleri, G. M., Megherbi, A., Diebakate, L., Collin, M., Hollebecque, A., Smolenschi, C., Valéry, M., Pudlarz, T., Fuerea, A. C., Boige, V., Ducreux, M., & Boilève, A. (2026). Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. European Journal of Cancer, 232, 116160. https://doi.org/10.1016/j.ejca.2025.116160
Vancouver
Debiais M, Tarabay A, Blanchet-Deverly S, Camilleri GM, Megherbi A, Diebakate L, et al. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. European Journal of Cancer. 2026;232:116160. doi:10.1016/j.ejca.2025.116160
BibTeX
@article{Debiais2026,
author = {Debiais, Mélanie and Tarabay, Anthony and Blanchet-Deverly, Sarah and Camilleri, Géraldine M and Megherbi, Alexandre and Diebakate, Laura and Collin, Maxime and Hollebecque, Antoine and Smolenschi, Cristina and Valéry, Marine and Pudlarz, Thomas and Fuerea, Alina Cristina and Boige, Valérie and Ducreux, Michel and Boilève, Alice},
title = {Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment},
journal = {European Journal of Cancer},
year = {2026},
volume = {232},
pages = {116160},
doi = {10.1016/j.ejca.2025.116160}
}
EUVIMED